Australia's most trusted
source of pharma news
Posted 16 July 2025 PM
Cell Therapies and Viral Vector Manufacturing Facility (VVMF) have joined forces to boost Australia’s onshore development and manufacture of Advanced Therapy Medicinal Products (ATMPs).
The contract development and manufacturing organisations (CDMOs) inked a memorandum of understanding (MoU) to explore strategic collaboration opportunities in the space, which they say underscores their joint commitment to expanding access to ATMPs for both Australian and international patients through clinical trials.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.